Skip to main content

Vilanterol/Umeclidinium versus Vilanterol/Glycopyrronium via Metered-Dose or Dry-Powder Inhaler in Indian Adults with COPD: Two Randomized Phase III Non-Inferiority Trials

In brief

Two vilanterol/umeclidinium inhalers meet non-inferiority for COPD lung function at 12 weeks

In two separate Indian trials involving 456 adults with COPD, vilanterol/umeclidinium delivered by either a metered-dose or dry-powder inhaler was non-inferior to vilanterol/glycopyrronium delivered by the same device type for lung function at 12 weeks. Side effects were mostly mild, with no serious events or deaths; longer-term results and evidence in broader populations are still needed.

Journal
Respiratory medicine (Q1)
Published
14 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Pankaj Bharat Bhai Vyas, Mitul Kumar Manubhai Chaudhari, Manish Kumar Mahendrasingh Jain, Jaydip Deb, Abhay Narendrabhai Javia, Avdhesh Trilok Chand Kumar, et al.
PMID
43034001
DOI
10.1016/j.rmed.2026.109299

Why clinicians should know about it

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality, particularly in low- and middle-income countries. Long-acting muscarinic antagonist (LAMA) plus long-acting β2-agonist (LABA) fixed-dose combinations (FDCs) are recommended for symptomatic at-risk patients, and are available on both metered-dose inhaler (MDI) and dry-powder inhaler (DPI) platforms. We evaluated new, locally manufactured MDI and DPI formulations of vilanterol/umeclidinium in Indian adults with COPD. METHODS: Two independent Phase III, randomized, parallel-group, active-controlled non-inferiority trials (MDI study: double-blind; DPI study: open-label) were conducted in India over 12 weeks, using a -100 mL non-inferiority margin for trough forced expiratory volume in 1 s (FEV1). The MDI study (n=226) enrolled adults aged 40-75 years with moderate-to-very-severe COPD, while the DPI study (n=230) enrolled patients with moderate-to-severe COPD. Each trial was analyzed separately, without pooling. RESULTS: Non-inferiority was demonstrated in both studies, with least-squares mean (LS mean) trough FEV1 differences of 49.18 mL (95% confidence interval [CI]: -24.08, 122.43) in the MDI study and 6.1 mL (95% CI: -47.32, 59.46) in the DPI study (Test - Reference; per-protocol population); both lower 95% CI bounds exceeded the -100 mL margin. No statistically significant between-arm differences were detected for secondary endpoints. Adverse events were predominantly mild, with no deaths or serious adverse events over 12 weeks. CONCLUSIONS: Vilanterol/umeclidinium FDC delivered via MDI and DPI was non-inferior to vilanterol/glycopyrronium FDC delivered by the same device type for change in trough FEV1 at 12 weeks in Indian adults with COPD. Longer-term studies in broader populations are needed. TRIAL REGISTRATION: Clinical Trials Registry of India (CTRI) CTRI/2025/03/082314 (MDI study) and CTRI/2025/06/088810 (DPI study).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.